SCHEMBL3248963

SCHEMBL3248963

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(S(=O)(=O)NC)cc3c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 1/20 0.44
GABRA1 P14867 3/20 0.43
GABRB2 P47870 3/20 0.43
HSD17B10 Q99714 3/20 0.42
MEN1 O00255 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
KMT2A Q03164 2/20 0.42
MAPK1 P28482 2/20 0.42
ALOX15 P16050 1/20 0.42
GABRB1 P18505 2/20 0.42
GABRA3 P34903 2/20 0.42
CLEC4M Q9H2X3 1/20 0.42
TP53 P04637 3/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
KDM4E B2RXH2 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3242035 0.89 GABRA1 (0.45) GABRA1GABRB2HSD17B10MEN1ALDH1A1
SCHEMBL3244720 0.88 GABRA1 (0.44) GABRA1GABRB2HSD17B10MEN1ALDH1A1
SCHEMBL3241955 0.88 MAPT (0.53) HSD17B10MEN1ALDH1A1HPGDKMT2A
SCHEMBL3254789 0.88 PKM (0.51) HSD17B10MEN1ALDH1A1HPGDKMT2A
SCHEMBL3250602 0.88 PARG (0.50) GABRA1GABRB2HSD17B10MEN1ALDH1A1
SCHEMBL3251351 0.87 MEN1 (0.61) HSD17B10MEN1ALDH1A1HPGDKMT2A
SCHEMBL3244575 0.87 POLB (0.42) GABRA1GABRB2HSD17B10MEN1ALDH1A1
SCHEMBL3252031 0.87 PKM (0.53) HSD17B10MEN1ALDH1A1HPGDKMT2A
SCHEMBL3254872 0.86 TDP1 (0.51) HSD17B10MEN1ALDH1A1HPGDKMT2A
SCHEMBL3248967 0.86 PKM (0.47) HSD17B10MEN1ALDH1A1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 TAS2R14 4728/4885GABRA1 3395/4885GABRB2 2245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.